Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Brii Biosciences Limited
腾盛博药生物科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
LICENSE AGREEMENT WITH JOINCARE

This announcement is made by the board of directors (the "**Board**") of Brii Biosciences Limited (the "**Company**") on a voluntary basis.

The Board is pleased to announce that the Company's wholly owned subsidiary, Brii Biosciences, Inc. ("**Brii US**"), has entered into an intellectual property license and technology transfer agreement (the "**Agreement**") with Joincare Pharmaceutical Group Industry Co., Ltd ("**Joincare**"). Pursuant to the Agreement, Joincare will obtain an exclusive license from Brii US for the research, development, and commercialization of BRII-693 in mainland China, Hong Kong, Macau and Taiwan (collectively, "**Greater China**").

Under the Agreement, Joincare will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii US has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events, as well as tiered royalties based on net product sales of BRII-693.

BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug-and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and pharmacokinetics profile in healthy non-Chinese and Chinese participants. The Company received new drug clinical trial approval from the Center for Drug Evaluation of China's National Medical Products Administration for a Phase 1 pharmacokinetics bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.

Dr. Zhi Hong, Chairman and Chief Executive Officer of the Company, commented: "the growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections."

Mr. Nanqi Lin, Chief Executive Officer of Joincare, stated, "the Company has a long stand track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by the Company's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options."

To the best of the knowledge, information and belief of the directors of the Company having made all reasonable enquiries, Joincare and its ultimate beneficial owners are independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

Cautionary Statement: There is no assurance that BRII-693 will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek advice from professional or financial advisers.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, July 4, 2025

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; and Dr. Martin J. Murphy Jr., Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.